Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.
Sorafenib, a multitargeted tyrosine kinase inhibitor, has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC). As the clinical use of sorafenib increases, many adverse effects have been reported, such as hand-foot skin reaction, diarrhea, anorexia, asthenia, alopecia, weight loss, hypertension and arterial thromboembolism. However, there are no prior reports of splenic infarction as an adverse effect of sorafenib. Here, a case of splenic infarction in a patient with HCC who was treated with sorafenib is reported. The patient had no other predisposing factors to explain the splenic infarction except for the administration of sorafenib. The splenic infarction improved after sorafenib was discontinued; however, the HCC progressed.
Department of Gastroenterology and Hepatology, Dong-A University Hospital, Dongdaesin-dong, Seo-gu, Busan 602-103, South Korea.
Sang Ock
SO
Kim
Sang Young
SY
Han
Yang Hyun
YH
Baek
Sung Wook
SW
Lee
Ji Sun
JS
Han
Byung Geun
BG
Kim
Jin Han
JH
Cho
Kyung Jin
KJ
Nam
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage; D001557:Benzenesulfonates / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D003287:Contrast Media / Q000494:pharmacology; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib; D013154:Spleen / Q000473:pathology*; D013159:Splenic Infarction / Q000139:chemically induced*; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D003287:Contrast Media; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D001241:Aspirin
N Engl J Med. 2008 Jul 24;359(4):378-90
18650514
Br J Cancer. 2007 Jun 18;96(12):1788-95
17519900
Blood. 2002 Dec 15;100(13):4272-90
12393615
JAMA. 2004 Oct 20;292(15):1867-74
15494585
J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9
17686822
J Clin Oncol. 2009 Oct 10;27(29):4865-73
19704059
J Clin Oncol. 2003 Sep 15;21(18):3542; author reply 3543
12972536
Am J Pathol. 1995 May;146(5):1029-39
7538264
Oncologist. 2010;15(2):130-41
20139170
J Clin Oncol. 2010 May 1;28(13):2280-5
20351323
Am J Physiol Cell Physiol. 2001 Jun;280(6):C1375-86
11350732
Chest. 2004 Sep;126(3 Suppl):234S-264S
15383474